StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Biogen (BIIB) Stock Edges Higher on Strong Earnings, Sales of New Alzheimer Drug Just $300k
October 20, 2021 9:00 AM
Biogen (NASDAQ: BIIB) stock is up about 1.5% in pre-open Wednesday after the company reported better-than-expected Q3 EPS.BIIB reported Q3 ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Earnings
FDA
Guidance
Hot Comments
Hot Earnings
Hot FDA News
Hot Guidance
Next Articles
Biogen (BIIB) PT Lowered to $390 at Oppenheimer
October 20, 2021 6:05 PM
Long-term Prospects for Biogen’s (BIIB) Aduhelm Remain Key Question - Analyst
October 20, 2021 8:21 AM
Biogen banks on government coverage to restart stalled Alzheimer's drug sales
October 20, 2021 7:07 AM
Biogen (BIIB) Tops Q3 EPS by 66c, Updates FY Guidance
October 20, 2021 7:05 AM
Biogen (BIIB) PT Lowered to $405 at UBS
October 20, 2021 3:54 AM